New to The Street to Broadcast Episode 686 Tonight on Bloomberg Television at 6:30 PM ESTNEW YORK CITY, NY / ACCESS Newswire / September 13, 2025 / New to The Street, one of America's longest-running financial media television platforms, will air its 686th episode nationwide on Bloomberg Television tonight, Saturday, September 13, 2025, at 6:30 PM EST.
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Resigns with New to The Street for Long-Form Interviews, National TV Commercials, Earned Media, and Accredited Investor EventsNEW YORK CITY, NY / ACCESS Newswire / September 6, 2025 / New to The Street, one of the nation's premier financial media platforms, today announced that Acurx Pharmaceuticals, Inc. (
NASDAQ:ACXP), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, has re-signed for a comprehensive media partnership.
New to The Street TV Commercial Campaigns Achieve Millions of Views with 87% Average Completion RateCross-platform synergy across NTTS TV, cable, social media, and NewsOut video press release amplification is delivering record-breaking visibility for public companies
New to the Street Announces Exclusive Bloomberg Lineup for October 11 at 6:30 PM ESTFeaturing ZAPP, NUBURU, ACURX Pharmaceuticals, The Sustainable Green Team, and SEKUR's Hack of the Week
Acurx Pharmaceuticals Inc. (NASDAQ: ACXP) Leading the Way in Monday Trading Based on Percentage GainAcurx Pharmaceuticals, Inc. (
NASDAQ: ACXP) is one of today’s top gainers. The company’s shares are currently up 42.08% on the day to $2.73.
Power Metallic (TSX.V: PNPN) Secures Largest Saudi License Amid June 2025 Gold Surge – Material Gains & More Stocks InsidePower Metallic Mines Inc. (TSXV: PNPN, OTCQB: PNPNF ) has reached a historic milestone by securing the largest exploration license in Saudi Arabia’s Jabal Sayid Belt , marking a major step in the company’s global expansion strategy. The awarded Jabal Baudan project spans over 200 square kilometers , targeting copper, gold, and zinc in one of the Kingdom’s most mineral-rich regions.
New to The Street's Documentary Specials Break Records: IMG Academy Surpasses 126,000 Views in Just 12 DaysPetVivo and Acurx Pharmaceuticals Exceed 200,000 Views as investor Demand for Long-Form Corporate Storytelling Surges
New to The Street Renews Acurx Pharmaceuticals (NASDAQ: ACXP) for Exclusive 6-Month Media Series Including Nationwide TV, Earned Media, and Expanded Digital ReachNEW YORK CITY, NEW YORK / ACCESS Newswire / April 16, 2025 / New to The Street, a premier business television and media platform, is proud to announce the renewal of its media partnership with Acurx Pharmaceuticals, Inc. (
NASDAQ:ACXP) for a new 6-month strategic campaign. The series will include long-form interviews airing as sponsored programming on Fox Business and Bloomberg Television, earned media placements, over 50 national commercials per month, and expanded visibility across New to The Street's 2.4M+ subscriber YouTube channel and digital networks.
New to The Street & Sight & Sound's Visionaries Series Premieres Tomorrow on Bloomberg at 6:30 PM EST, Featuring Acurx Pharmaceuticals NASDAQ:ACXPNEW YORK CITY, NEW YORK / ACCESS Newswire / March 14, 2025 / The highly anticipated Visionaries Series from New to The Street and Sight & Sound premieres tomorrow on Bloomberg at 6:30 PM EST as sponsored programming, featuring Acurx Pharmaceuticals. This compelling episode follows the incredible journey of co-founders David P. Luci, Robert J. DeLuccia, and Robert G. Shawah - from their college days to building and exiting successful pharmaceutical companies, and ultimately coming together to launch Acurx Pharmaceuticals.
New to the Street to Broadcast Show 627 on Bloomberg Television at 6:30 PM EST Today as Sponsored ProgrammingFeatured Segments Include Kevin Harrington on The Sustainable Green Team, Atlas Clear, High Performance Battery, and Modular Medical
Acurx Pharmaceuticals to Present at the Microcap Conference, January 28, 2025 - January 30, 2025STATEN ISLAND, NY / ACCESSWIRE / December 11, 2024 / Acurx Pharmaceuticals, Inc. ("Acurx" or the "Company") (
NASDAQ:ACXP), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced that David P. Luci, President & Chief Executive Officer, will be presenting at The Microcap Conference, which will take place January 28 to January 30, 2025 at the Borgata Hotel, Atlantic City, New Jersey.
Bloomberg’s “New to The Street” Segment by PetVivo Inc. (OTCQB: PETV) Stocks to Watch This Week inside….New to The Street, the premier platform for introducing cutting-edge companies, is excited about Bloomberg TV's interviews which aired on Saturday, October 12, 2024 featured key industry leaders , sponsored by PetVivo Holdings Inc. (PETV), including: Zapp Electric Vehicles Group Limited (
NASDAQ: ZAPP), NUBURU (NYSEAM: BURU), Acurx Pharmaceuticals, Inc. (
NASDAQ: ACXP), The Sustainable Green Team (OTC: SGTM) see company information below:
New to the Street Announces Exclusive Bloomberg Lineup for Saturday October 12 at 6:30 PM ESTFeaturing ZAPP, NUBURU, ACURX Pharmaceuticals, The Sustainable Green Team, and SEKUR's Hack of the Week
New to the Street TV Series on Bloomberg and Fox Business, Innovative Companies Spotlighted: ACXP, TNXP, PETV, SWISF, GEVI, CLNVThe New to the Street TV series interviews are broadcast nationally on Bloomberg and Fox Business News, targeting investors. These segments offer a glimpse into companies spotlighted or soon to be featured on these networks.
Acurx Pharmaceuticals’ Phase 2b Results For Ibezapolstat Bests Standard Of Care Vancomycin To Treat C. Difficile ($ACXP)Acurx Pharmaceuticals, Inc. (
NASDAQ: ACXP) stock may present an investment opportunity that is too good to ignore. That assessment is more than warranted; it's justified, based on results from its Phase 2b clinical trial of its lead antibiotic candidate, ibezapolstat, for treating patients with Clostridioides difficile Infection ( C. difficile, CDI). The data is more than compelling; it puts the target ACXP aims for, front-line treatment designation, in its crosshairs. And plenty supports hitting the bullseye.
Acurx Pharmaceuticals Share Price And Volume Are Surging Ahead Of Phase 2b Trial Data Release ($ACXP)Acurx Pharmaceuticals, Inc. (
NASDAQ: ACXP) stock is getting massive interest. Of course, the question is- why? Speculation is that its related to ACXP nearing a data release for its Phase 2b clinical trial targeting treatment for C. difficile, one of the most common causes of healthcare-associated infections in U.S. hospitals that is estimated to affect over 450,000 patients annually and, worse, is associated with approximately 20,000 deaths annually. That's just in the U.S. Using a global measure, that number gets a significant multiple.
